Lipid-based Nanocarriers for siRNA Delivery: Challenges, Strategies and the Lessons Learned from the DODAX: MO...

Area of Science:

• Gene therapy
• Molecular biology
• Nanotechnology

Background:

• RNA interference (RNAi) is a powerful gene therapy tool with significant therapeutic potential.
• Efficient delivery of small interfering RNA (siRNA) remains a major hurdle for clinical translation.
• Liposomes are attractive nanocarriers for siRNA due to low toxicity and favorable properties.

Purpose of the Study:

• To review RNAi as a therapeutic approach and delivery challenges.
• To explore lipid-based nanocarriers, specifically liposomes, for siRNA delivery.
• To examine the relationship between biophysical properties and biological performance of nanocarrier systems.

Main Methods:

• Literature review focusing on RNAi, gene therapy, and nanocarrier systems.
• Analysis of liposome properties for siRNA complexation, transfection, and pharmacokinetics.
• Exploration of the dioctadecyldimethylammonium:monoolein (DODAX: MO) system as a case study.

Main Results:

• Liposomes demonstrate potential as safe siRNA delivery vehicles, protecting nucleic acids and enhancing circulation time.
• Key challenges for liposome-mediated RNAi include achieving target-cell specificity and efficient endosomal escape.
• Understanding the biophysical properties of nanocarriers is crucial for optimizing biological performance.

Conclusions:

• Liposomes offer a viable strategy for siRNA delivery in gene therapy, improving safety and efficacy.
• Further research is needed to overcome delivery-related obstacles for widespread clinical adoption of RNAi therapies.
• Establishing structure-activity relationships for nanocarriers is essential for advancing gene therapy applications.